Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quisinostat in High-Risk Uveal Melanoma
NCT06932757Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- May 2025
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of quisinostat in Uveal melanoma (UM), sponsored by University of Miami. Primary endpoint: Distant Metastasis-Free Survival Rate at 36 months. Started May 2025; status: recruiting.
02
Drugs
quisinostat
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT06932757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932757.